表紙
市場調查報告書

藥物安全檢測的全球市場 (各臨床實驗階段,服務業者,各地區):市場規模,產業分析,今後展望·成長可能性,價格趨勢,市場佔有率,未來預測

Pharmacovigilance Market Size By Clinical Trial Phase, By Service Provider Industry Analysis Report, Regional Outlook, Application Potential, Competitive Market Share & Forecast, 2018 - 2024

出版商 Global Market Insights Inc. 商品編碼 622789
出版日期 內容資訊 英文 162 Pages
商品交期: 2-3個工作天內
價格
Back to Top
藥物安全檢測的全球市場 (各臨床實驗階段,服務業者,各地區):市場規模,產業分析,今後展望·成長可能性,價格趨勢,市場佔有率,未來預測 Pharmacovigilance Market Size By Clinical Trial Phase, By Service Provider Industry Analysis Report, Regional Outlook, Application Potential, Competitive Market Share & Forecast, 2018 - 2024
出版日期: 2018年09月11日內容資訊: 英文 162 Pages
簡介

本報告提供全球藥物安全檢測 (醫藥品安全性監視)的市場相關分析,提供產業的基本結構和向心力,技術·法規環境,主要的推動及阻礙市場要素,臨床實驗階段 (各期/階段) ·服務供應商·各地區的市場趨勢預測 (過去4年·今後8年份),主要企業的簡介·業績·策略等調查。

第1章 分析方法與市場範圍

第2章 摘要整理

第3章 數位Health產業分析

  • 產業區分
  • 產業形勢 (總計12年)
  • 產業的影響要素
    • 成長促進因素
    • 產業的陷阱與課題
  • 成長可能性分析
    • 各臨床實驗階段 (各期,階段)
    • 服務業者的各類型
    • 新的經營模式
  • 波特的五力分析
  • 法規環境
  • 藥物安全檢測的報告系統
  • 企業佔有率分析
    • 市場策略一覽
  • 藥物安全檢測·服務的市場環境
  • PESTEL分析

第4章 藥物安全檢測市場:各臨床實驗階段

  • 市場主要趨勢:臨床實驗階段 (各期)
  • 前臨床
    • 市場規模的實際成果值·預測值:各地區 (總計12年份)
  • 第一階段
  • 第二階段
  • 第三階段
  • 第四階段

第5章 藥物安全檢測市場:服務業者

  • 市場主要趨勢:服務業者
  • 公司內部部門
  • 外部委託業者

第6章 藥物安全檢測市場:各地區

  • 市場主要趨勢
  • 北美 (美國,加拿大)
    • 市場規模的實際成果值·預測值:各國 (總計12年份)
    • 市場規模的實際成果值·預測值:各臨床實驗階段 (總計12年份)
    • 市場規模的實際成果值·預測值:服務業者 (總計12年份)
  • 歐洲 (德國,英國,西班牙,義大利,法國)
  • 亞太地區 (日本,中國,印度,澳洲)
  • 南美 (阿根廷,巴西,墨西哥)
  • 中東·非洲 (南非,UAE,沙烏地阿拉伯,卡達,以色列)

第7章 企業簡介

  • Accenture
    • 產業概要,財務資料,產品概要,策略部署預測,SWOT分析
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • Clinquest Group B.V.
  • Cognizant Technology Solutions Corporation
  • Ecron Acunova Ltd.
  • F. Hoffmann-La Roche Ltd.
  • Foresight Group International AG
  • GlaxoSmithKline Plc.
  • HCL Technologies
  • IBM Corporation
  • ICON plc
  • iGATE Corporation (Capgemini)
  • Infosys Ltd.
  • InVentiv Health Clinical
  • Ipca Laboratories Ltd.
  • IQVIA (QuintilesIMS)
  • Itclinical
  • Janssen Research & Development, LLC
  • Laboratory Corporation of America Holdings
  • Novartis AG
  • Oracle Corporation
  • Parexel International Corporation
  • Pfizer
  • Sanofi Aventis
  • TCS
  • Telerx (C3i Solutions)
  • Wipro

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: 853

Title:
Pharmacovigilance Market Size By Clinical Trial Phase (Preclinical, Phase I, Phase II, Phase III, Phase IV), By Service Provider (In-house, Contract Outsourcing) Industry Analysis Report, Regional Outlook (U.S., Canada, UK, Germany, Spain, Italy, France, China, Japan, India, Australia, Argentina, Brazil, Mexico, South Africa, Saudi Arabia, UAE, Qatar, Israel), Application Potential, Competitive Market Share & Forecast, 2018 - 2024.

Pharmacovigilance Market will exceed USD 8.0 billion by 2024; as per a new research report.

Rising incidences of adverse drug reactions (ADRs) leading to increase in morbidity and mortality rates across the globe is primary driver for pharmacovigilance market growth. Approximately 5% of the total hospitalizations every year are due to adverse drug reactions creating a huge healthcare burden across the globe. Such factors lead to increase in demand for monitoring drug safety and efficacy thereby augmenting pharmacovigilance industry growth.

Upsurge in drug development by pharmaceutical companies owing to increasing chronic diseases worldwide is another major factor contributing towards market growth. In addition, regulatory authorities such as European Medicines Agency and U.S. FDA have intensified drug safety mandates prior and post commercialization of drugs further boosting industry size.

Rising trend of outsourcing pharmacovigilance services to contract research organizations in developing countries will further favor pharmacovigilance industry expansion. However, data security risks along with dearth of skilled healthcare personnel will hinder market growth over the forecast timeline.

Pharmacovigilance phase IV clinical trial business segment market was USD 2.9 billion in 2017 owing to increasing drug safety concerns and growing public health awareness about adverse drug events. It aims at continuous safety surveillance through adverse event monitoring till the drug is marketed.

In-house pharmacovigilance business segment was valued at USD 1.7 billion in 2017 and is expected to show considerable growth by 2024. Issues pertaining to data confidentiality, data safety, accountability and commitment associated with outsourcing services are some of the prime factors favoring companies to opt for in-house pharmacovigilance.

U.S. pharmacovigilance market was valued over USD 1.2 billion in 2017. Rising death rates due to adverse drug reactions and growing patient concerns relating to safety and efficacy of drugs in the country are prominent factors for business growth. Increasing funding for clinical trials along with presence of well-established industry players in the U.S. will further drive U.S. pharmacovigilance market.

Italy pharmacovigilance market is projected to grow at a rapid 10.6% CAGR from 2018 to 2024 due to presence of favorable regulatory authorities in the country. The Italian Medicines Agency (Agenzia Italiana del Farmaco, AIFA) regulates the national pharmacovigilance system in association with the rules laid down at EU level by the EMA. The organization is responsible for improving pharmacovigilance knowledge and increase the number of ADR reports up to the gold standard level established by the WHO. Such factors will drive regional growth in the coming years.

Increasing outsourcing of clinical trials to developing countries such as India and China due to low operating costs coupled with availability of large diverse patient pool for conducting clinical trials in these countries will foster Asia Pacific pharmacovigilance market growth.

Few notable industry players are IQVIA (QuintilesIMS), InVentiv Health Clinical, LabCorp, PAREXEL, Accenture, Cognizant, and TCS. Strategic collaborations, mergers and acquisitions, and providing customized services are key sustainability strategies adopted by these industry players.

Table of Contents

Chapter 1. Methodology

  • 1.1. Methodology
  • 1.2. Market definitions
  • 1.3. Forecast parameters
  • 1.4. Data sources
    • 1.4.1. Secondary
      • 1.4.1.1. Paid sources
      • 1.4.1.2. Unpaid sources
    • 1.4.2. Primary

Chapter 2. Executive Summary

  • 2.1. Pharmacovigilance industry 360 degree synopsis, 2013 - 2024 (USD Million)
    • 2.1.1. Business trends
    • 2.1.2. Clinical trial phase trends
    • 2.1.3. Service provider trends
    • 2.1.4. Regional trends

Chapter 3. Pharmacovigilance Industry Insights

  • 3.1. Industry segmentation
  • 3.2. Industry landscape, 2013 - 2024
  • 3.3. Industry impact forces
    • 3.3.1. Growth drivers
      • 3.3.1.1. Increase in adoption rate of outsourcing services in Asia Pacific
      • 3.3.1.2. Increasing consumption of drugs in developed regions
      • 3.3.1.3. Rise in adverse drug reactions (ADR) and drug toxicity
      • 3.3.1.4. Increasing acceptance of personalized medicine in developed regions
      • 3.3.1.5. Effective global harmonization practices
    • 3.3.2. Industry pitfalls and challenges
      • 3.3.2.1. Dearth of skilled personnel
      • 3.3.2.2. High risk associated with data security
  • 3.4. Growth potential analysis
    • 3.4.1. By clinical trial phase
    • 3.4.2. By service provider
  • 3.5. New business models
  • 3.6. Porter's analysis
  • 3.7. Regulatory landscape
  • 3.8. Pharmacovigilance reporting system
  • 3.9. Competitive landscape
    • 3.9.1. Company market share analysis, 2017
    • 3.9.2. Strategy dashboard
  • 3.10. Pharmacovigilance service landscape
  • 3.11. PESTEL analysis

Chapter 4. Pharmacovigilance Market, By Clinical Trial Phase

  • 4.1. Key segment trends
  • 4.2. Preclinical
    • 4.2.1. Market size, by region, 2013-2024 (USD Million)
  • 4.3. Phase I
    • 4.3.1. Market size, by region, 2013-2024 (USD Million)
  • 4.4. Phase II
    • 4.4.1. Market size, by region, 2013-2024 (USD Million)
  • 4.5. Phase III
    • 4.5.1. Market size, by region, 2013-2024 (USD Million)
  • 4.6. Phase IV
    • 4.6.1. Market size, by region, 2013-2024 (USD Million)

Chapter 5. Pharmacovigilance Market, By Service Provider

  • 5.1. Key segment trends
  • 5.2. In-house
    • 5.2.1. Market size, by region, 2013-2024 (USD Million)
  • 5.3. Contract outsourcing
    • 5.3.1. Market size, by region, 2013-2024 (USD Million)

Chapter 6. Pharmacovigilance Market, By Region

  • 6.1. Key regional trends
  • 6.2. North America
    • 6.2.1. Market size, by country, 2013 - 2024 (USD Million)
    • 6.2.2. Market size, by clinical trial phase, 2013 - 2024 (USD Million)
    • 6.2.3. Market size, by service provider, 2013 - 2024 (USD Million)
    • 6.2.4. U.S.
      • 6.2.4.1. Market size, by country, 2013 - 2024 (USD Million)
      • 6.2.4.2. Market size, by clinical trial phase, 2013 - 2024 (USD Million)
      • 6.2.4.3. Market size, by service provider, 2013 - 2024 (USD Million)
    • 6.2.5. Canada
      • 6.2.5.1. Market size, by country, 2013 - 2024 (USD Million)
      • 6.2.5.2. Market size, by clinical trial phase, 2013 - 2024 (USD Million)
      • 6.2.5.3. Market size, by service provider, 2013 - 2024 (USD Million)
  • 6.3. Europe
    • 6.3.1. Market size, by country, 2013 - 2024 (USD Million)
    • 6.3.2. Market size, by clinical trial phase, 2013 - 2024 (USD Million)
    • 6.3.3. Market size, by service provider, 2013 - 2024 (USD Million)
    • 6.3.4. Germany
      • 6.3.4.1. Market size, by country, 2013 - 2024 (USD Million)
      • 6.3.4.2. Market size, by clinical trial phase, 2013 - 2024 (USD Million)
      • 6.3.4.3. Market size, by service provider, 2013 - 2024 (USD Million)
    • 6.3.5. UK
      • 6.3.5.1. Market size, by country, 2013 - 2024 (USD Million)
      • 6.3.5.2. Market size, by clinical trial phase, 2013 - 2024 (USD Million)
      • 6.3.5.3. Market size, by service provider, 2013 - 2024 (USD Million)
    • 6.3.6. Spain
      • 6.3.6.1. Market size, by country, 2013 - 2024 (USD Million)
      • 6.3.6.2. Market size, by clinical trial phase, 2013 - 2024 (USD Million)
      • 6.3.6.3. Market size, by service provider, 2013 - 2024 (USD Million)
    • 6.3.7. Italy
      • 6.3.7.1. Market size, by country, 2013 - 2024 (USD Million)
      • 6.3.7.2. Market size, by clinical trial phase, 2013 - 2024 (USD Million)
      • 6.3.7.3. Market size, by service provider, 2013 - 2024 (USD Million)
    • 6.3.8. France
      • 6.3.8.1. Market size, by country, 2013 - 2024 (USD Million)
      • 6.3.8.2. Market size, by clinical trial phase, 2013 - 2024 (USD Million)
      • 6.3.8.3. Market size, by service provider, 2013 - 2024 (USD Million)
  • 6.4. Asia Pacific
    • 6.4.1. Market size, by country, 2013 - 2024 (USD Million)
    • 6.4.2. Market size, by clinical trial phase, 2013 - 2024 (USD Million)
    • 6.4.3. Market size, by service provider, 2013 - 2024 (USD Million)
    • 6.4.4. Japan
      • 6.4.4.1. Market size, by country, 2013 - 2024 (USD Million)
      • 6.4.4.2. Market size, by clinical trial phase, 2013 - 2024 (USD Million)
      • 6.4.4.3. Market size, by service provider, 2013 - 2024 (USD Million)
    • 6.4.5. China
      • 6.4.5.1. Market size, by country, 2013 - 2024 (USD Million)
      • 6.4.5.2. Market size, by clinical trial phase, 2013 - 2024 (USD Million)
      • 6.4.5.3. Market size, by service provider, 2013 - 2024 (USD Million)
    • 6.4.6. India
      • 6.4.6.1. Market size, by country, 2013 - 2024 (USD Million)
      • 6.4.6.2. Market size, by clinical trial phase, 2013 - 2024 (USD Million)
      • 6.4.6.3. Market size, by service provider, 2013 - 2024 (USD Million)
    • 6.4.7. Australia
      • 6.4.7.1. Market size, by country, 2013 - 2024 (USD Million)
      • 6.4.7.2. Market size, by clinical trial phase, 2013 - 2024 (USD Million)
      • 6.4.7.3. Market size, by service provider, 2013 - 2024 (USD Million)
  • 6.5. Latin America
    • 6.5.1. Market size, by country, 2013 - 2024 (USD Million)
    • 6.5.2. Market size, by clinical trial phase, 2013 - 2024 (USD Million)
    • 6.5.3. Market size, by service provider, 2013 - 2024 (USD Million)
    • 6.5.4. Argentina
      • 6.5.4.1. Market size, by country, 2013 - 2024 (USD Million)
      • 6.5.4.2. Market size, by clinical trial phase, 2013 - 2024 (USD Million)
      • 6.5.4.3. Market size, by service provider, 2013 - 2024 (USD Million)
    • 6.5.5. Brazil
      • 6.5.5.1. Market size, by country, 2013 - 2024 (USD Million)
      • 6.5.5.2. Market size, by clinical trial phase, 2013 - 2024 (USD Million)
      • 6.5.5.3. Market size, by service provider, 2013 - 2024 (USD Million)
    • 6.5.6. Mexico
      • 6.5.6.1. Market size, by country, 2013 - 2024 (USD Million)
      • 6.5.6.2. Market size, by clinical trial phase, 2013 - 2024 (USD Million)
      • 6.5.6.3. Market size, by service provider, 2013 - 2024 (USD Million)
  • 6.6. MEA
    • 6.6.1. Market size, by country, 2013 - 2024 (USD Million)
    • 6.6.2. Market size, by clinical trial phase, 2013 - 2024 (USD Million)
    • 6.6.3. Market size, by service provider, 2013 - 2024 (USD Million)
    • 6.6.4. South Africa
      • 6.6.4.1. Market size, by country, 2013 - 2024 (USD Million)
      • 6.6.4.2. Market size, by clinical trial phase, 2013 - 2024 (USD Million)
      • 6.6.4.3. Market size, by service provider, 2013 - 2024 (USD Million)
    • 6.6.5. UAE
      • 6.6.5.1. Market size, by country, 2013 - 2024 (USD Million)
      • 6.6.5.2. Market size, by clinical trial phase, 2013 - 2024 (USD Million)
      • 6.6.5.3. Market size, by service provider, 2013 - 2024 (USD Million)
    • 6.6.6. Saudi Arabia
      • 6.6.6.1. Market size, by country, 2013 - 2024 (USD Million)
      • 6.6.6.2. Market size, by clinical trial phase, 2013 - 2024 (USD Million)
      • 6.6.6.3. Market size, by service provider, 2013 - 2024 (USD Million)
    • 6.6.7. Qatar
      • 6.6.7.1. Market size, by country, 2013 - 2024 (USD Million)
      • 6.6.7.2. Market size, by clinical trial phase, 2013 - 2024 (USD Million)
      • 6.6.7.3. Market size, by service provider, 2013 - 2024 (USD Million)
    • 6.6.8. Israel
      • 6.6.8.1. Market size, by country, 2013 - 2024 (USD Million)
      • 6.6.8.2. Market size, by clinical trial phase, 2013 - 2024 (USD Million)
      • 6.6.8.3. Market size, by service provider, 2013 - 2024 (USD Million)

Chapter 7. Company Profiles

  • 7.1. Accenture
    • 7.1.1. Business overview
    • 7.1.2. Financial data
    • 7.1.3. Product landscape
    • 7.1.4. Strategic outlook
    • 7.1.5. SWOT analysis
  • 7.2. Boehringer Ingelheim
    • 7.2.1. Business overview
    • 7.2.2. Financial data
    • 7.2.3. Product landscape
    • 7.2.4. Strategic outlook
    • 7.2.5. SWOT analysis
  • 7.3. Bristol-Myers Squibb
    • 7.3.1. Business overview
    • 7.3.2. Financial data
    • 7.3.3. Product landscape
    • 7.3.4. Strategic outlook
    • 7.3.5. SWOT analysis
  • 7.4. Clinquest Group B.V.
    • 7.4.1. Business overview
    • 7.4.2. Financial data
    • 7.4.3. Product landscape
    • 7.4.4. Strategic outlook
    • 7.4.5. SWOT analysis
  • 7.5. Cognizant Technology Solutions Corporation
    • 7.5.1. Business overview
    • 7.5.2. Financial data
    • 7.5.3. Product landscape
    • 7.5.4. Strategic outlook
    • 7.5.5. SWOT analysis
  • 7.6. Ecron Acunova Ltd.
    • 7.6.1. Business overview
    • 7.6.2. Financial data
    • 7.6.3. Product landscape
    • 7.6.4. Strategic outlook
    • 7.6.5. SWOT analysis
  • 7.7. F. Hoffmann-La Roche Ltd.
    • 7.7.1. Business overview
    • 7.7.2. Financial data
    • 7.7.3. Product landscape
    • 7.7.4. Strategic outlook
    • 7.7.5. SWOT analysis
  • 7.8. Foresight Group International AG
    • 7.8.1. Business overview
    • 7.8.2. Financial data
    • 7.8.3. Product landscape
    • 7.8.4. Strategic outlook
    • 7.8.5. SWOT analysis
  • 7.9. GlaxoSmithKline Plc
    • 7.9.1. Business overview
    • 7.9.2. Financial data
    • 7.9.3. Product landscape
    • 7.9.4. Strategic outlook
    • 7.9.5. SWOT analysis
  • 7.10. HCL Technologies
    • 7.10.1. Business overview
    • 7.10.2. Financial data
    • 7.10.3. Product landscape
    • 7.10.4. Strategic outlook
    • 7.10.5. SWOT analysis
  • 7.11. IBM Corporation
    • 7.11.1. Business overview
    • 7.11.2. Financial data
    • 7.11.3. Product landscape
    • 7.11.4. Strategic outlook
    • 7.11.5. SWOT analysis
  • 7.12. ICON plc
    • 7.12.1. Business overview
    • 7.12.2. Financial data
    • 7.12.3. Product landscape
    • 7.12.4. Strategic outlook
    • 7.12.5. SWOT analysis
  • 7.13. iGATE Corporation (Capgemini)
    • 7.13.1. Business overview
    • 7.13.2. Financial data
    • 7.13.3. Product landscape
    • 7.13.4. Strategic outlook
    • 7.13.5. SWOT analysis
  • 7.14. Infosys Ltd.
    • 7.14.1. Business overview
    • 7.14.2. Financial data
    • 7.14.3. Product landscape
    • 7.14.4. Strategic outlook
    • 7.14.5. SWOT analysis
  • 7.15. InVentiv Health Clinical
    • 7.15.1. Business overview
    • 7.15.2. Financial data
    • 7.15.3. Product landscape
    • 7.15.4. Strategic outlook
    • 7.15.5. SWOT analysis
  • 7.16. Ipca Laboratories Ltd.
    • 7.16.1. Business overview
    • 7.16.2. Financial data
    • 7.16.3. Product landscape
    • 7.16.4. Strategic outlook
    • 7.16.5. SWOT analysis
  • 7.17. IQVIA (QuintilesIMS)
    • 7.17.1. Business overview
    • 7.17.2. Financial data
    • 7.17.3. Product landscape
    • 7.17.4. Strategic outlook
    • 7.17.5. SWOT analysis
  • 7.18. ITclinical
    • 7.18.1. Business overview
    • 7.18.2. Financial data
    • 7.18.3. Product landscape
    • 7.18.4. Strategic outlook
    • 7.18.5. SWOT analysis
  • 7.19. Janssen Research & Development, LLC
    • 7.19.1. Business overview
    • 7.19.2. Financial data
    • 7.19.3. Product landscape
    • 7.19.4. Strategic outlook
    • 7.19.5. SWOT analysis
  • 7.20. Laboratory Corporation of America Holdings
    • 7.20.1. Business overview
    • 7.20.2. Financial data
    • 7.20.3. Product landscape
    • 7.20.4. Strategic outlook
    • 7.20.5. SWOT analysis
  • 7.21. Novartis AG
    • 7.21.1. Business overview
    • 7.21.2. Financial data
    • 7.21.3. Product landscape
    • 7.21.4. Strategic outlook
    • 7.21.5. SWOT analysis
  • 7.22. Oracle Corporation
    • 7.22.1. Business overview
    • 7.22.2. Financial data
    • 7.22.3. Product landscape
    • 7.22.4. Strategic outlook
    • 7.22.5. SWOT analysis
  • 7.23. PAREXEL International Corporation
    • 7.23.1. Business overview
    • 7.23.2. Financial data
    • 7.23.3. Product landscape
    • 7.23.4. Strategic outlook
    • 7.23.5. SWOT analysis
  • 7.24. Pfizer
    • 7.24.1. Business overview
    • 7.24.2. Financial data
    • 7.24.3. Product landscape
    • 7.24.4. Strategic outlook
    • 7.24.5. SWOT analysis
  • 7.25. Sanofi Aventis
    • 7.25.1. Business overview
    • 7.25.2. Financial data
    • 7.25.3. Product landscape
    • 7.25.4. Strategic outlook
    • 7.25.5. SWOT analysis
  • 7.26. TCS
    • 7.26.1. Business overview
    • 7.26.2. Financial data
    • 7.26.3. Product landscape
    • 7.26.4. Strategic outlook
    • 7.26.5. SWOT analysis
  • 7.27. Telerx (C3i Solutions)
    • 7.27.1. Business overview
    • 7.27.2. Financial data
    • 7.27.3. Product landscape
    • 7.27.4. Strategic outlook
    • 7.27.5. SWOT analysis
  • 7.28. Wipro
    • 7.28.1. Business overview
    • 7.28.2. Financial data
    • 7.28.3. Product landscape
    • 7.28.4. Strategic outlook
    • 7.28.5. SWOT analysis

Data Tables

  • TABLE 1. Pharmacovigilance industry 360 0 synopsis, 2013 - 2024
  • TABLE 2. Global pharmacovigilance market, 2013 - 2024 (USD Million)
  • TABLE 3. Global pharmacovigilance market, by clinical trial phase, 2013 - 2024 (USD Million)
  • TABLE 4. Global pharmacovigilance market, by service provider, 2013 - 2024 (USD Million)
  • TABLE 5. Global pharmacovigilance market, by region, 2013 - 2024 (USD Million)
  • TABLE 6. Industry impact forces
  • TABLE 7. Pharmacovigilance regulatory initiatives
  • TABLE 8. Preclinical market size, by region, 2013 - 2024 (USD Million)
  • TABLE 9. Phase I market size, by region, 2013 - 2024 (USD Million)
  • TABLE 10. Phase II market size, by region, 2013 - 2024 (USD Million)
  • TABLE 11. Phase III market size, by region, 2013 - 2024 (USD Million)
  • TABLE 12. Phase IV market size, by region, 2013 - 2024 (USD Million)
  • TABLE 13. In-House market size, by region, 2013 - 2024 (USD Million)
  • TABLE 14. Contract outsourcing market size, by region, 2013 - 2024 (USD Million)
  • TABLE 15. North America pharmacovigilance market, by country, 2013 - 2024 (USD Million)
  • TABLE 16. North America pharmacovigilance market, by clinical trial phase, 2013 - 2024 (USD Million)
  • TABLE 17. North America pharmacovigilance market, by service provider, 2013 - 2024 (USD Million)
  • TABLE 18. U.S. pharmacovigilance market, by clinical trial phase, 2013 - 2024 (USD Million)
  • TABLE 19. U.S. pharmacovigilance market, by service provider, 2013 - 2024 (USD Million)
  • TABLE 20. Canada pharmacovigilance market, by clinical trial phase, 2013 - 2024 (USD Million)
  • TABLE 21. Canada pharmacovigilance market, by service provider, 2013 - 2024 (USD Million)
  • TABLE 22. Europe pharmacovigilance market, by country, 2013 - 2024 (USD Million)
  • TABLE 23. Europe pharmacovigilance market, by clinical trial phase, 2013 - 2024 (USD Million)
  • TABLE 24. Europe pharmacovigilance market, by service provider, 2013 - 2024 (USD Million)
  • TABLE 25. Germany pharmacovigilance market, by clinical trial phase, 2013 - 2024 (USD Million)
  • TABLE 26. Germany pharmacovigilance market, by service provider, 2013 - 2024 (USD Million)
  • TABLE 27. UK pharmacovigilance market, by clinical trial phase, 2013 - 2024 (USD Million)
  • TABLE 28. UK pharmacovigilance market, by service provider, 2013 - 2024 (USD Million)
  • TABLE 29. Spain pharmacovigilance market, by clinical trial phase, 2013 - 2024 (USD Million)
  • TABLE 30. Spain pharmacovigilance market, by service provider, 2013 - 2024 (USD Million)
  • TABLE 31. Italy pharmacovigilance market, by clinical trial phase, 2013 - 2024 (USD Million)
  • TABLE 32. Italy pharmacovigilance market, by service provider, 2013 - 2024 (USD Million)
  • TABLE 33. France pharmacovigilance market, by clinical trial phase, 2013 - 2024 (USD Million)
  • TABLE 34. France pharmacovigilance market, by service provider, 2013 - 2024 (USD Million)
  • TABLE 35. Asia Pacific pharmacovigilance market, by country, 2013 - 2024 (USD Million)
  • TABLE 36. Asia Pacific pharmacovigilance market, by clinical trial phase, 2013 - 2024 (USD Million)
  • TABLE 37. Asia Pacific pharmacovigilance market, by service provider, 2013 - 2024 (USD Million)
  • TABLE 38. Japan pharmacovigilance market, by clinical trial phase, 2013 - 2024 (USD Million)
  • TABLE 39. Japan pharmacovigilance market, by service provider, 2013 - 2024 (USD Million)
  • TABLE 40. China pharmacovigilance market, by clinical trial phase, 2013 - 2024 (USD Million)
  • TABLE 41. China pharmacovigilance market, by service provider, 2013 - 2024 (USD Million)
  • TABLE 42. India pharmacovigilance market, by clinical trial phase, 2013 - 2024 (USD Million)
  • TABLE 43. India pharmacovigilance market, by service provider, 2013 - 2024 (USD Million)
  • TABLE 44. Australia pharmacovigilance market, by clinical trial phase, 2013 - 2024 (USD Million)
  • TABLE 45. Australia pharmacovigilance market, by service provider, 2013 - 2024 (USD Million)
  • TABLE 46. Latin America pharmacovigilance market, by country, 2013 - 2024 (USD Million)
  • TABLE 47. Latin America pharmacovigilance market, by clinical trial phase, 2013 - 2024 (USD Million)
  • TABLE 48. Latin America pharmacovigilance market, by service provider, 2013 - 2024 (USD Million)
  • TABLE 49. Argentina pharmacovigilance market, by clinical trial phase, 2013 - 2024 (USD Million)
  • TABLE 50. Argentina pharmacovigilance market, by service provider, 2013 - 2024 (USD Million)
  • TABLE 51. Brazil pharmacovigilance market, by clinical trial phase, 2013 - 2024 (USD Million)
  • TABLE 52. Brazil pharmacovigilance market, by service provider, 2013 - 2024 (USD Million)
  • TABLE 53. Mexico pharmacovigilance market, by clinical trial phase, 2013 - 2024 (USD Million)
  • TABLE 54. Mexico pharmacovigilance market, by service provider, 2013 - 2024 (USD Million)
  • TABLE 55. MEA pharmacovigilance market, by country, 2013 - 2024 (USD Million)
  • TABLE 56. MEA pharmacovigilance market, by clinical trial phase, 2013 - 2024 (USD Million)
  • TABLE 57. MEA pharmacovigilance market, by service provider, 2013 - 2024 (USD Million)
  • TABLE 58. South Africa pharmacovigilance market, by clinical trial phase, 2013 - 2024 (USD Million)
  • TABLE 59. South Africa pharmacovigilance market, by service provider, 2013 - 2024 (USD Million)
  • TABLE 60. UAE pharmacovigilance market, by clinical trial phase, 2013 - 2024 (USD Million)
  • TABLE 61. UAE pharmacovigilance market, by service provider, 2013 - 2024 (USD Million)
  • TABLE 62. Saudi Arabia pharmacovigilance market, by clinical trial phase, 2013 - 2024 (USD Million)
  • TABLE 63. Saudi Arabia pharmacovigilance market, by service provider, 2013 - 2024 (USD Million)
  • TABLE 64. Qatar pharmacovigilance market, by clinical trial phase, 2013 - 2024 (USD Million)
  • TABLE 65. Qatar pharmacovigilance market, by service provider, 2013 - 2024 (USD Million)
  • TABLE 66. Israel pharmacovigilance market, by clinical trial phase, 2013 - 2024 (USD Million)
  • TABLE 67. Israel pharmacovigilance market, by service provider, 2013 - 2024 (USD Million)

Charts & Figures

  • FIG 1. Industry segmentation
  • FIG 2. Global pharmacovigilance market size, 2013 - 2024 (USD Million)
  • FIG 3. Growth potential analysis, by clinical trial phase
  • FIG 4. Growth potential analysis, by service provider
  • FIG 5. Types of pharmacovigilance outsourcing vendors
  • FIG 6. Porter's analysis
  • FIG 7. Company market share analysis, 2017
  • FIG 8. Strategy dashboard
  • FIG 9. PESTEL analysis
Back to Top